Almac Group Launches claraT – A Unique, Software-driven Gene Expression Report
October 19, 2018
Craigavon, N.I., 19 October 2018 – Almac Diagnostic Services has launched claraT – a unique software-driven solution, classifying biologically relevant gene expression signatures into a comprehensive, easy-to-interpret report.
The claraT report will benefit BioPharma and Academic biomarker discovery and translational research. Clients are provided with an interactive report that allows the easy visualisation of the key discriminating biologies within both the study cohort and an individual tumour sample.
claraT classifies relevant published gene expression signatures, alongside Almac’s own proprietary assays and single gene targets linked to multiple key biologies, according to the well-established 10 Hallmarks of Cancer. The claraT report is a pan-cancer solution generated from raw gene expression data, utilising Almac’s RNA-Sequencing Service.
RNA-Sequencing data is extremely complex and difficult to interpret, often requiring extensive bioinformatics expertise. Almac has developed proprietary bioinformatics pipelines to report this complex data through claraT in a simplified manner, helping to save time and maximise the understanding of any dataset more quickly.
The claraT report classifies using the Hallmarks of Cancer for easy interpretation. Initial launch content includes 35 gene expression signatures and 30 single gene drug targets (in addition to other biology linked genes). The first three featured hallmark biologies included are: immuno-oncology (IO), epithelial to mesenchymal transition (EMT) and angiogenesis. Almac will continue to expand the claraT report by developing content to ultimately cover all 10 Hallmarks of Cancer.
Michael Sloan, Global VP of Commercial Operations, Almac Diagnostic Services stated:
“RNA-Sequencing produces vast amounts of complex raw data that can be difficult to interpret. We believe claraT offers a unique and highly cost-effective solution to this problem for BioPharma clients. From a single tumour sample sent to Almac’s labs, claraT provides multiple biologically relevant signature readouts in an easy to interpret report, saving time and allowing researchers to identify key patterns of gene expression within their cohort.
“claraT further enhances Almac Diagnostic Services’ capabilities within RNA expression profiling. The value of RNA alongside DNA in stratified medicine is slowly starting to be realised and Almac are hoping to provide further proof of its importance with our claraT gene expression report.
We are excited by the potential effect claraT may have for future oncology biomarker discovery research.”
For further information on claraT visit the www.almacgroup.com/diagnostics/claratreport
About claraT Report
The results displayed in the claraT report are for research use only (RUO) and are not to be used for diagnostic or prognostic purposes, including predicting responsiveness to a particular therapy.
About Almac Diagnostic Services
Almac Diagnostic Services is a global stratified medicine company specialising in biomarker driven clinical trials. The company is focused on the discovery, development and commercialisation of diagnostic and companion diagnostic tests. We partner with biopharma companies to provide solutions ranging from biomarker discovery to CDx development including regulatory submissions and commercialisation. We also facilitate biomarker clinical trial management and clinical test delivery from our CLIA-accredited labs. The tests developed at Almac Diagnostic Services have a wide range of applications including patient selection, and are utilised in phase I to phase III registrational clinical trials.
For more information visit: www.almacgroup.com/diagnostics.
About Almac Group
A unique culture delivering exceptional solutions
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Our innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has grown organically over the past five decades now employing over 5600 highly skilled personnel across 18 facilities including Europe, the US and Asia. Click here to view our facilities.
We have a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.